ÂÜÀòÂÒÂ×

Ray Furey, J.D., was appointed Executive Vice President, General Counsel and Corporate Secretary in December 2022. Mr. Furey joined Rigel from Turning Point Therapeutics (now BMS) in San Diego where he held the role of Senior Vice President and Chief Compliance Officer, and also served as interim General Counsel. Prior to joining Turning Point, Mr. Furey was Senior Vice President and Chief Compliance Officer at Portola Pharmaceuticals (now Alexion). He has held senior executive roles at Mallinckrodt and Questcor Pharmaceuticals and was the Corporate Compliance Officer at OSI Pharmaceuticals (now Astellas). Mr. Furey spent 17 years at Genentech (now Roche) in various roles at the beginning of his career. He holds a J.D. from Fordham University School of Law, an M.B.A. from San Francisco State University, and a B.A. from Trinity College Dublin.